<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03425721</url>
  </required_header>
  <id_info>
    <org_study_id>CMO-US-FAS-0486</org_study_id>
    <nct_id>NCT03425721</nct_id>
  </id_info>
  <brief_title>Histological and Microbiological Evaluation of Late Occurring Nodules With Hyaluronic Acid Dermal Fillers</brief_title>
  <official_title>Histological and Microbiological Evaluation of Late Occurring Nodules With Hyaluronic Acid Dermal Fillers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine if HA dermal filler late occurring (&gt; 4 weeks and &lt;2 years) nodules
      are associated with bacterial contamination (independent of filler type) and to characterize
      the histological response.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Histological Sampling</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Histological lab assessment of biopsy sample for analysis of Hematoxylin and eosin (H&amp;E), orcein, periodic acid-Schiff, gram stain and immunohistochemistry (IHC), with a histopathology assessment to identify possible presence and location of bacteria, mycobacteria, fungus, mold, and/or yeast and the immune/inflammation response within the biopsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiological Sampling</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Microbiology lab assessment of biopsy sample for analysis of the presence and species of bacteria/mycobacteria within the biopsy.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Dermal Nodule</condition>
  <arm_group>
    <arm_group_label>All Participants</arm_group_label>
    <description>Subjects who present with late occurring nodules, occurring more than 4 weeks but less than 2 years after the latest injection of any HA soft tissue filler. This population will only include subjects who, before receiving the HA soft tissue filer were naïve to soft tissue fillers or had previously received only HA-based soft tissue fillers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>No Intervention is administered in this study.</description>
    <arm_group_label>All Participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who present with late occurring nodules, occurring more than 4 weeks but less than
        2 years after the latest injection of any HA soft tissue filler.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have only received HA fillers (no limitation on the brand(s)/product(s) of HA filler
             used; multiple product use is allowed).

          -  Present with an unresolved nodule (inflammatory or non-inflammatory) which was first
             observed &gt; 4 weeks and &gt; 2 years after most recent HA filler treatment and is
             determined to be greater than 3 millimeters (mm) in diameter by palpation

        Exclusion Criteria:

          -  Have received non-HA fillers (e.g. polyacrylamide, calcium hydroxyapatite,
             poly-L-lactic acid, polymethylmethacrylate, silicone, expanded
             polytetrafluoroethylene, collagen) including mixes with HA fillers anywhere in the
             face.

          -  Are currently enrolled in a dermal filler clinical trial or previously enrolled in a
             dermal filler clinical trial with randomized treatment in which the type of dermal
             filler is unknown (i.e. non-HA filler arm of study).

          -  Have history of keloid or hypertrophic scarring

          -  Have received intralesional intervention for the nodule (e.g. hyaluronidase,
             corticosteroids, antibiotics, 5-fluorouracil).

          -  Are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Maltman</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Registry Team</last_name>
    <phone>877-277-8566</phone>
    <email>IR-CTRegistration@Allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Skin Care and Laser Physicians (SCLP) of Beverly Hills</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>92269</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-246-0495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assure Surgical, P.C.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>516-295-0404</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Integrated Specialist Healthcare</name>
      <address>
        <city>Miranda</city>
        <state>New South Wales</state>
        <zip>2228</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Insitute of Victoria</name>
      <address>
        <city>South Yarra</city>
        <state>Victoria</state>
        <zip>3141</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>61 398264966</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aalst Dermatology Clinic</name>
      <address>
        <city>Aalst</city>
        <zip>43-9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>325-378-1899</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carruthers and Humphrey Cosmetic Medicine</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nowell Solish</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5R3N8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Klinik Für Dermatologie Und Allergologie Der Ruhr-Universität Bochum St. Josef Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>D-44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hautzentrum Koeln</name>
      <address>
        <city>Cologne</city>
        <zip>50996</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skin Concept</name>
      <address>
        <city>Muenchen</city>
        <zip>80333</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Servizio Ambulatoriale di Medicina</name>
      <address>
        <city>Rome</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>3 11 070 40110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Knysna Advanced Medical Centre</name>
      <address>
        <city>Knysna</city>
        <zip>6571</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>27 11 356 6206</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClincalTrials.com, please contact IR-CTRegistration.com for assistance.</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <last_update_submitted>June 4, 2019</last_update_submitted>
  <last_update_submitted_qc>June 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

